A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomas

Overview of attention for article published in Cancer (0008543X), April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter: 16 X users

Readers on

mendeley: 45 Mendeley

So far, Altmetric has seen 16 X posts from 16 X users, with an upper bound of 54,188 followers.

RT @JTrentMDPhD: Gemcitabine plus docetaxel placebo arm: 21.1 month median OS 5.6 month median PFS in metastatic soft‐tissue sarcoma. No be…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 12 additional X posts.